Reference change value for HbA1c in patients with type 2 diabetes mellitus

Area of Science:

• Clinical Chemistry
• Endocrinology
• Diabetes Mellitus Research

Background:

• Glycohemoglobin (HbA1c) is a key biomarker for assessing long-term glycemic control in diabetes.
• Understanding biological variation and reference change values for HbA1c is essential for accurate clinical interpretation of serial measurements.
• Previous studies have not fully elucidated these parameters in clinically stable type 2 diabetes patients.

Purpose of the Study:

• To estimate the reference change value (RCV) and steady-state biological variation of HbA1c.
• To analyze these variations across different glycemic control groups (good, acceptable, poor) in type 2 diabetes.
• To establish analytical goals for HbA1c assays based on biological variation.

Main Methods:

• Serial HbA1c measurements using turbidimetric inhibition immunoassay in 47 stable type 2 diabetes patients.
• Calculation of analytical imprecision, biological variation, and RCV for different glycemic control categories.
• Classification of patients based on 1999 American Diabetes Association (ADA) HbA1c guidelines.

Main Results:

• Steady-state biological variation for HbA1c was 7.9% (good), 5.4% (acceptable), and 3.9% (poor) control groups.
• Absolute RCV ranged from 1.37% to 1.50%, with relative RCV between 17.8% and 29.1%.
• Analytical goals, defined as half the biological variation, were below 3.9% for well-controlled patients.

Conclusions:

• The study provides essential data on HbA1c biological variation and RCV in type 2 diabetes.
• These findings aid in distinguishing true biological changes from analytical noise in HbA1c monitoring.
• The established analytical goals support the development of more precise and reliable HbA1c assays for improved diabetes care.